Prevention of allergic reactions during oxaliplatin desensitization through inhibition of Bruton tyrosine kinase

Acute infusion reactions to oxaliplatin, a chemotherapeutic used to treat gastrointestinal cancers, are observed in about 20% of patients. Rapid drug desensitization (RDD) protocols often allow the continuation of oxaliplatin in patients with no alternative options. Breakthrough symptoms, including anaphylaxis, can still occur during RDD.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Brief report Source Type: research